Research recommendations coming out of this guidance What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer? Is primary radical cystectomy more effective than primary intravesical BCG (Bacille Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes? In people with high-risk non-muscle-invasive bladder cancer, are these follow-up regimens equally effective in terms of identification of progression, cost effectiveness and health-related quality of life? - Cystoscopic follow-up at 3, 6, 12, 18, 24, 36 and 48 months, and then annually, interspersed with non-invasive urinary tests. - Cystoscopic follow-up at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months, and then annually thereafter. In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of biomarkers enable patients to select more effective treatment, and improve their outcomes, compared with treatment selected without biomarkers? Is symptom-based review as effective as scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder cancer? Outcomes of interest are overall survival, health-related quality of life, resource use and cost.
What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?
Is primary radical cystectomy more effective than primary intravesical BCG (Bacille Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?
In people with high-risk non-muscle-invasive bladder cancer, are these follow-up regimens equally effective in terms of identification of progression, cost effectiveness and health-related quality of life? - Cystoscopic follow-up at 3, 6, 12, 18, 24, 36 and 48 months, and then annually, interspersed with non-invasive urinary tests. - Cystoscopic follow-up at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 months, and then annually thereafter.
In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of biomarkers enable patients to select more effective treatment, and improve their outcomes, compared with treatment selected without biomarkers?
Is symptom-based review as effective as scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder cancer? Outcomes of interest are overall survival, health-related quality of life, resource use and cost.